Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
about
The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) familyPathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer's DiseaseExpression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degenerationStructure analysis reveals the flexibility of the ADAMTS-5 active siteBiglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis.ADAMTS-12: a multifaced metalloproteinase in arthritis and inflammation10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furinExtracellular matrix molecules: potential targets in pharmacotherapy.Rose hip and its constituent galactolipids confer cartilage protection by modulating cytokine, and chemokine expression.Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5Survey of the therapeutic approach and efficacy of pentosan polysulfate for the prevention and treatment of equine osteoarthritis in veterinary practice in Australia.CCN1 (Cyr61) Is Overexpressed in Human Osteoarthritic Cartilage and Inhibits ADAMTS-4 (Aggrecanase 1) Activity.Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.Glucan HBP-A increase type II collagen expression of chondrocytes in vitro and tissue engineered cartilage in vivo.ADAMTS-7 exhibits elevated expression in cartilage of osteonecrosis of femoral head and has a positive correlation with TNF- α and NF- κ B P65Genetic and functional studies of the intervertebral disc: a novel murine intervertebral disc modelStandardized butanol fraction of WIN-34B suppresses cartilage destruction via inhibited production of matrix metalloproteinase and inflammatory mediator in osteoarthritis human cartilage explants culture and chondrocytes.Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis.Selective MMP13 inhibitors.The role of ADAMTSs in arthritisHistone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.Molecular mechanisms of the cartilage-specific microRNA-140 in osteoarthritis.c-Maf Transcription Factor Regulates ADAMTS-12 Expression in Human Chondrogenic CellsMatrix-embedded cytokines to simulate osteoarthritis-like cartilage microenvironments.Novel Insights into Osteoarthritis Joint Pathology from Studies in Mice.Investigational drugs for the treatment of osteoarthritis.Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-ĸB signaling pathways in human chondrocytes.Computational Insights into ADAMTS4, ADAMTS5 and MMP13 Inhibitor Selectivity.Joint aging and chondrocyte cell death.SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes.Design, synthesis, and preliminary biological evaluation of pyrrolo[3,4-c]quinolin-1-one and oxoisoindoline derivatives as aggrecanase inhibitors.Suramin increases cartilage proteoglycan accumulation in vitro and protects against joint damage triggered by papain injection in mouse knees in vivo.Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.The IL-1β/AP-1/miR-30a/ADAMTS-5 axis regulates cartilage matrix degradation in human osteoarthritis.The nutraceutical flavonoid luteolin inhibits ADAMTS-4 and ADAMTS-5 aggrecanase activities
P2860
Q21146633-DF67EC1B-07A0-4957-849E-8FCE4DED2B8FQ26738884-84FC1B7A-CE8E-4178-893C-304D1C9D3935Q27009408-749DF941-D25A-4833-B397-55C98D690A86Q27667156-0EB6147A-96F5-458E-A558-51D3D60F47FAQ33597165-E1D2F566-1354-4FBD-8369-103AF8125FF0Q33607501-499CBD17-3FE8-4860-BDB8-077A5EA0FCEAQ33678954-DF8B8044-B327-4B71-8BBC-9A85B76B6FD6Q33694487-400D86DF-E1D5-4524-996C-1C32BA11D3CCQ34066453-A32B089D-8147-4543-BE52-D53EE482C793Q34283551-7779D309-03B0-4D4E-AFA5-54C6C01D755FQ34449528-78008647-A548-49AF-A5B1-EE9B3308AF01Q34464193-99B1BBAB-3D70-4FC1-9C45-5604D305C274Q34605944-F793370C-4FF0-40E6-8BD4-42501A3810AFQ34824573-12844866-A191-4DD2-BDEA-F88FB11D9070Q35026762-4F008778-091F-449B-A526-ABED50752AFCQ35490110-E9F9B8F8-746E-4950-A7E6-610C80B1693DQ36574611-F1F7E926-47D0-464E-8D20-3B3A155365D3Q36901003-A6F0C915-252D-4C55-AA52-6086924486F5Q37701372-691FD920-BC37-4D62-9B66-067DB765616CQ37825835-D5E726D0-6D4D-4B1F-88C6-518B7759641DQ38008692-A767364D-2E85-440D-AF97-8765D40EB58DQ38128702-22CF70CF-5FC6-408C-A900-09999829567DQ38316661-A38F1387-EAC1-4EE7-A125-BA75C2C81C11Q38317248-98A8EF7C-CC86-40F8-B6A1-94E729FFFB5FQ38424856-68E85461-D3B4-44A5-886F-9AE6ED33C483Q38597565-7EC94DA2-9402-4830-B60D-AEAD925228E5Q38973400-6BDD023A-5949-4E52-B698-53E79925EEEEQ39540092-6C7F2E47-F7CC-47B2-89B0-F58A29534480Q41877821-17FD0618-B889-4870-BCF4-665E69AB70B0Q42878322-52D6E11D-6F29-418B-911D-2E3F067AEE83Q43105023-1405EF62-DB5C-4790-9B8D-E6BC3C3ABC23Q47148493-E715EB21-0E08-493E-82C3-D2DC3BAA1092Q48543248-72A93F66-FDDF-4F67-BF95-F53EF67B3B3BQ55025580-D3CE5E44-2B07-4B39-96E1-1ED9BB433D14Q57082622-C13E806F-706C-4BE8-9F43-2E7B7949BADE
P2860
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@en
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@nl
type
label
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@en
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@nl
prefLabel
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@en
Drug insight: aggrecanases as therapeutic targets for osteoarthritis.
@nl
P2860
P356
P1476
Drug insight: aggrecanases as therapeutic targets for osteoarthritis
@en
P2093
Amanda J Fosang
Christopher B Little
P2860
P304
P356
10.1038/NCPRHEUM0841
P577
2008-06-24T00:00:00Z